Thermo Fisher Scientific Inc

Most Recent

  • Raw materials in a steel factory
    Company & Industry Overviews

    Materials Sector Stocks Weigh Market Down, Might Be Time to Buy

    By Rachel Curry
  • uploads///life sciences
    Company & Industry Overviews

    What Lies Ahead for Thermo Fisher’s Life Sciences Solutions Business?

    TMO’s Life Sciences Solutions segment registered revenue growth of around 11% in 1Q16. The company reported strong growth in biosciences.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Analyst Recommendations for Thermo Fisher Scientific

    Based on recommendations by 21 broker firms surveyed by Bloomberg, the consensus rating for Thermo Fisher Scientific was “buy” from 19 of the firms and “hold” from two of the firms.

    By Sarah Collins
  • uploads///SAFETY REVENUES
    Company & Industry Overviews

    How BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17

    Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the MFEGX
    Macroeconomic Analysis

    Analyzing the MFS Growth Fund’s 2015 Portfolio

    The information technology, consumer discretionary, and healthcare sectors form the core of the MFS Growth Fund.

    By David Ashworth
  • uploads///Xamarin
    Miscellaneous

    Microsoft Infiltrates the Mobile App Space: The Xamarin Acquisition

    On February 24, Microsoft announced that it will acquire Xamarin, a mobile app platform provider. Financial details of the deal were not disclosed.

    By Anne Shields
  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///oncology
    Company & Industry Overviews

    Varian Medical Systems’ Oncology Devices Are Key to Sales Growth

    Varian Medical Systems commands the majority share of the oncology device market in the United States.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    What Analysts Predict for Thermo Fisher’s 2Q17 Revenues

    Wall Street estimates that Thermo Fisher Scientific’s (TMO) 2Q17 revenue will come in at ~$4.9 billion, a rise of ~8.5% on a YoY (year-over-year) basis.

    By Sarah Collins
  • uploads/// guidance
    Company & Industry Overviews

    What’s Expected of Baxter International in Fiscal 2017?

    Baxter International (BAX) has updated its sales guidance growth from 2.0%–3.0% to approximately 4.0% on a constant currency basis.

    By Sarah Collins
  • uploads///FCX
    Fund Managers

    Paulson & Co. eliminates position in Freeport-McMoRan

    Freeport-McMoRan is the world’s largest publicly traded copper producer. It posted revenue of $5.7 billion, down 7.6%, saying, results “reflect lower oil volumes and price realizations for copper, gold and oil.”

    By Samantha Nielson
  • uploads///COV
    Fund Managers

    Paulson & Co. ups position in Covidien

    The Ireland-based Covidien is engaged in the development, manufacture, and sale of healthcare products for use in clinical and home settings. Its fourth-quarter net sales increased 7% to $2.73 billion.

    By Samantha Nielson
  • uploads///earnings estimates
    Company & Industry Overviews

    Boston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance

    In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    Thermo Fisher Scientific: What’s Been Driving Growth?

    In this series, we discuss the major drivers of Thermo Fisher Scientific’s valuation, stock performance. and growth fundamentals.

    By Sarah Collins
  • What Are Leon Cooperman’s Top Holdings?
    Financials

    What Are Leon Cooperman’s Top Holdings?

    In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

    By Rabindra Samanta
  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Zimmer Biomet Stock Regains Momentum: What’s Driving Growth?

    Ximmer Biomet (ZBH) has risen 2.1% since its 1Q17 earnings release on April 27, 2017. The results exceeded analysts’ estimates, but ZBH lowered its 2017 guidance.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///oncology
    Company & Industry Overviews

    TMO’s Oncomine Target Test Launch Will Boost This Business

    On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.

    By Sarah Collins
  • uploads///core strategies
    Company & Industry Overviews

    How Are Stryker’s Core Strategies Working Toward Its Growth?

    Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BD’s Stock Price Performance after Recent 52-Week High

    On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

    By Sarah Collins
  • uploads///analyst recommendations
    Earnings Report

    Analyst Recommendations for TMO Stock after 1Q18 Earnings Release

    As of April 25 and according to a recent Reuters survey of 16 research firms, TMO stock is rated a “strong buy” by eight analysts.

    By Sarah Collins
  • uploads///Paulson
    Fund Managers

    Key positions traded by Paulson & Co. in 3Q14

    Paulson & Co. was founded in 1994 by John Paulson. Unconfirmed sources say the firm posted a 14% loss in its event-driven Paulson Advantage fund in October.

    By Samantha Nielson
  • uploads///eps estimates
    Earnings Report

    Can Boston Scientific Surpass Its Earnings Estimates in 3Q17?

    BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.

    By Sarah Collins
  • uploads///lifesicences focus areas
    Company & Industry Overviews

    BD Lifesciences’s Performance and Core Focus Areas

    BDX’s Lifesciences business generated revenues of ~$3.8 billion in fiscal 2016, ended September 30, 2016.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Can BAX Stock Maintain Momentum after Recent Highs?

    BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///patheon overview
    Company & Industry Overviews

    Thermo Fisher’s Next Big Deal in the Medical Device Industry

    On May 15, 2017, Thermo Fisher (TMO) announced the acquisition of Patheon (PTHN) for ~$7.2 billion, which includes ~$2 billion of net debt assumption.

    By Sarah Collins
  • Fund Managers

    Paulson & Co. opens a new position in PetSmart

    PetSmart announced a broad cost-reduction strategy that will target all areas of the business. The company said it expects to realize savings before the end of fiscal 2015.

    By Samantha Nielson
  • uploads///SALES ESTIMATE
    Earnings Report

    Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up

    On April 25, Thermo Fisher Scientific (TMO) announced its results for 1Q18. Its revenues rose 23% YoY to $5.9 billion.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///stock price
    Company & Industry Overviews

    How Has Thermo Fisher Scientific’s Stock Performed Recently?

    Thermo Fisher Scientific (TMO) was trading at $140.3 on November 28, 2016.

    By Sarah Collins
  • Healthcare

    Why is leverage a double-edged sword for companies like Apple?

    Corporate bond issuance in the U.S. reached $1.4 trillion in 2013, according to the Securities Industry and Financial Markets Association (SIFMA), a new record.

    By Phalguni Soni
  • uploads///Graph
    Company & Industry Overviews

    How Will Abbott Laboratories Benefit from Its Alere Acquisition?

    On April 14, 2017, Abbott Laboratories (ABT) agreed to acquire point-of-care diagnostics player Alere (ALR) for an equity value of ~$5.3 billion.

    By Margaret Patrick
  • uploads///Diabetes
    Company & Industry Overviews

    What to Expect from Medtronic’s Diabetes Segment

    In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.

    By Daniel Collins
  • uploads///analyst recommendations
    Earnings Report

    How Wall Street Views Stryker After its 3Q17 Results

    Analysts’ recommendations on Stryker Stryker (SYK) announced its 3Q17 earnings results on October 26, 2017. In this article, we’ll look at analysts’ ratings, recommendations, and target prices for Stryker over the next 12 months. As of October 30, 2017, of 28 investment research companies surveyed by Reuters, 17 (61%) recommended “buy” for Stryker, nine recommended “hold,” and two recommended […]

    By Sarah Collins
  • uploads///revenues by segment
    Earnings Report

    Assessing Abbott’s 3Q17 Expectations by Segment

    In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    What Analysts Recommend for BDX before Its 3Q17 Results

    Becton Dickinson (BDX) plans to release its fiscal 3Q17 results on August 3. In a survey of 15 firms, ~66.7% of the analysts rated BDX as a “buy,” and 33.3% rated it as a “hold.”

    By Sarah Collins
  • uploads///VALUATION
    Company & Industry Overviews

    What’s Thermo Fisher Scientific’s Latest Valuation?

    After the release of its 2Q16 earnings results on July 28, 2016, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) multiple of 17.9x–18.5x.

    By Sarah Collins
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///Third Point
    Basic Materials

    In 4Q 2013, which positions does Third Point bet on?

    Third Point revealed new positions and sell outs during the fourth quarter in its 13F filing this month.

    By Samantha Nielson
  • uploads///core strategies
    Company & Industry Overviews

    How Stryker’s Margins Are Driven by Its CTG Program

    Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

    By Sarah Collins
  • uploads///TMO
    Company & Industry Overviews

    Thermo Fisher Scientific’s Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    Taking Stock of Thermo Fisher as the Year Wraps Up

    In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///lab _
    Earnings Report

    Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

    Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

    By Mike Benson
  • uploads///analysis _
    Company & Industry Overviews

    How Johnson & Johnson’s Medical Device Business Stands Now

    Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Thermo Fisher’s Third-Quarter Revenue Estimates

    The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

    By Mike Benson
  • uploads///analysis _
    Earnings Report

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

    By Mike Benson
  • uploads///earnings estimates
    Earnings Report

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

    By Sarah Collins
  • uploads///sales estimates
    Earnings Report

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

    By Sarah Collins
  • uploads///RMD ana reco
    Company & Industry Overviews

    What ResMed’s Valuation Trend Indicates

    The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

    By Kenneth Smith
  • uploads///A ana reco
    Company & Industry Overviews

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

    By Kenneth Smith
  • uploads///WAT ana reco
    Company & Industry Overviews

    What Waters Corporation’s Valuation Trend Indicates

    In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

    By Kenneth Smith
  • uploads///valuation
    Company & Industry Overviews

    Is Abbott Laboratories Trading at a High Valuation in September?

    Abbott stock has been gaining momentum recently, and its valuation has improved.

    By Sarah Collins
  • uploads///DGX
    Company & Industry Overviews

    Taking Stock of Quest Diagnostics’ Recent Acquisitions

    Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues.

    By Kenneth Smith
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    What’s the Upside Potential of Thermo Fisher Scientific Stock?

    So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.

    By Kenneth Smith
  • uploads///TMO drivres
    Company & Industry Overviews

    What’s Driving the Growth in Thermo Fisher Scientific’s Segments?

    Thermo Fisher Scientific (TMO) operates in four business segments.

    By Kenneth Smith
  • uploads///hologic recommendations
    Company & Industry Overviews

    Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock

    As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

    By Mike Benson
  • uploads///chemist _
    Company & Industry Overviews

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

    By Mike Benson
  • uploads///Diagnostics
    Company & Industry Overviews

    A Performance Overview of Roche’s Diagnostics Division

    In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Haemonetics

    Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Thermo Fisher’s Q2 2018 Estimates: Revenue Growth Expected

    Wall Street analysts expect Thermo Fisher’s (TMO) revenues to reflect 18.1% growth to $5.9 billion during the second quarter.

    By Mike Benson
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Can HOLX Stock Rebound from Its Recent Lows?

    On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.

    By Sarah Collins
  • uploads///q highlights
    Company & Industry Overviews

    Discussing BDX’s Recent Stock Price Performance

    On March 28, 2018, Becton, Dickinson and Company (BDX) ended trading at a closing price of $212.43.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    What Are Thermo Fisher Scientific’s Current Valuations?

    As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How TMO Stock Has Performed Recently

    On March 14, 2018, Thermo Fisher Scientific (TMO) closed at $213.46 per share.

    By Sarah Collins
  • uploads/// capital deployment strategy
    Company & Industry Overviews

    What Investors Should Know about TMO’s Dividends

    On March 14, 2018, Thermo Fisher Scientific (TMO) stock started trading ex-dividend.

    By Sarah Collins
  • uploads///REVENUE PROFILE
    Company & Industry Overviews

    A Look at Thermo Fisher Scientific’s Recent Research Partnerships

    Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, and consumables, diagnostics and research software, and services.

    By Sarah Collins
  • uploads///HPIC SYSTEM
    Company & Industry Overviews

    A Look at TMO’s New High Pressure Ion Chromatography System

    On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of its new high-pressure Ion Chromatography System.

    By Sarah Collins
  • uploads///lab management sytem
    Company & Industry Overviews

    TMO’s Advanced Laboratory Management System Could Gain Market Share

    On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.

    By Sarah Collins
  • uploads///CAPITAL ALLOCATION STRATEGY
    Company & Industry Overviews

    A Look at Stryker’s Recent Dividend Announcement

    On February 7, 2018, Stryker (SYK) announced a quarterly dividend of $0.47 per share.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Abbott Laboratories: ABT Stock’s Wall Street Recommendations

    Abbott Laboratories (ABT) has recorded strong growth recently, registering stellar performance.

    By Sarah Collins
  • uploads///SALES Q
    Company & Industry Overviews

    Boston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates

    Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.

    By Sarah Collins
  • uploads///conclusion of the contract __
    Company & Industry Overviews

    How Bard Acquisition Could Benefit BD

    Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.

    By Sarah Collins
  • uploads///conclusion of the contract __
    Company & Industry Overviews

    What BD Expects for 2018

    BD posted 1Q18 results as a standalone company and didn’t include Bard sales in 1Q18.

    By Sarah Collins
  • uploads///conclusion of the contract __
    Company & Industry Overviews

    How BD Stock Has Performed in the Last Year

    On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.

    By Sarah Collins
  • uploads///key launches
    Company & Industry Overviews

    Why Abbott Laboratories Plans to Focus on Organic Growth in 2018

    Abbott’s plan will be to focus on organic growth over the next year and going forward, after a slew of major acquisitions and strategic divestitures.

    By Sarah Collins
  • uploads///STOOCK PRICE
    Earnings Report

    Thermo Fisher Scientific Stock Hit 52-Week High on January 23

    On January 23, 2018, Thermo Fisher Scientific (TMO) traded at its 52-week high of $217.22. However, it closed at $214.55.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results

    Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

    By Sarah Collins
  • uploads///AXDX RD Expenses
    Company & Industry Overviews

    What Are Accelerate Diagnostics’ Key Strengths?

    In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

    By Kenneth Smith
  • uploads///AXDX revenue growth
    Company & Industry Overviews

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

    By Kenneth Smith
  • uploads///How it works
    Company & Industry Overviews

    What’s the Competitive Landscape for Accelerate Diagnostics?

    Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

    By Kenneth Smith
  • uploads///recommendations
    Company & Industry Overviews

    Stryker Stock: Wall Street Recommendations and Target Price

    Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17.

    By Sarah Collins
  • uploads///q guidance
    Company & Industry Overviews

    Baxter International Expected to Post Strong 4Q17 Results

    Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street Shows Confidence in BAX Stock

    Analysts’ recommendations Baxter International (BAX), one of the United States’ leading medical technology companies, offers renal and hospital solutions to healthcare providers. The company has witnessed strong growth momentum recently, and Wall Street has grown increasingly bullish on the company’s growth prospects. In this article, we’ll look at analysts’ recent recommendations, ratings, and price targets for BAX stock. […]

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    A Look at Thermo Fisher Scientific’s Recent Stock Price Performance

    TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.

    By Sarah Collins
  • uploads///leerink
    Company & Industry Overviews

    Why Leerink Swann Lowered Its 2018 Estimates for TMO Stock

    On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street Analysts’ ‘Buy’ Ratings and Recommendations on TMO Stock

    On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.

    By Sarah Collins
  • uploads///product segments
    Company & Industry Overviews

    TMO’s Acquisition from EPTEK Technology Could Boost Its China Opportunity

    On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.

    By Sarah Collins
  • uploads///oncology
    Company & Industry Overviews

    TMO’s Oncomine Dx Target Test Gets CMS Coverage

    On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).

    By Sarah Collins
  • uploads///digital science capabilities
    Company & Industry Overviews

    Thermo Fisher Scientific’s Deepening Ties with Sema4

    Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

    By Sarah Collins
  • uploads///GENETIC ANALYSIS GROWTH STRATEGY
    Company & Industry Overviews

    TMO’s Launch of New Research Assay for Cancer

    On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.